A Study of Ustekinumab (STELARA) in Chinese Participants With Moderately to Severely Active Crohn's Disease

PHASE4CompletedINTERVENTIONAL
Enrollment

182

Participants

Timeline

Start Date

December 10, 2021

Primary Completion Date

May 18, 2025

Study Completion Date

May 18, 2025

Conditions
Crohn Disease
Interventions
DRUG

Ustekinumab

Ustekinumab will be administered as an IV injection in induction phase and as a SC injection in maintenance phase.

Trial Locations (29)

100191

Peking University Third Hospital, Beijing

100700

The Military General Hospital of Beijing PLA, Beijing

110004

Shengjing Hospital Of China Medical University, Shenyang

200040

Huashan Hospital Fudan University, Shanghai

200072

Shanghai 10th Peoples Hospital, Shanghai

200120

The second Xiangya Hospital of Central South University, Changsha

Shanghai East Hospital, Shanghai

210000

Zhongda Hospital Southeast University, Nanjing

210029

Jiangsu Province Hospital, Nanjing

213000

Changzhou No 2 Peoples Hospital, Changzhou

214023

Wuxi People s Hospital, Wuxi

215168

The Second Hospital Affiliated To Suzhou University, Suzhou

225001

Yangzhou First People's Hospital, Yangzhou

230001

Anhui Province Hospital, Hefei

310003

The Second Affiliated Hospital of Zhejiang University, Hangzhou

310016

Sir Run Run Shaw Hospital Zhejiang University School of Medicine, Hangzhou

313099

Huzhou central hospital, Huzhou

315000

Ningbo medical center lihuili hospital, Ningbo

321000

Jinhua municipal central hospital, Jinhua

330006

The First Affiliated Hospital of NanChang University, Nanchang

350005

The First Affiliated Hospital of Fujian Medical University, Fuzhou

430030

Tongji Hospital, Tongji Medical College of HUST, Wuhan

430060

Renmin Hospital of Wuhan University, Wuhan

510080

The First Affiliated Hospital Sun Yat sen University, Guangzhou

510180

Guangzhou First Municipal People's Hospital, Guangzhou

518036

Peking University Shenzhen Hospital, Shenzhen

563000

Affiliated Hospital of Zunyi Medical University, Zunyi

610041

West China Hospital Sichuan University, Chengdu

Unknown

The Sixth Affiliated Hospital of Sun Yat-sen University, Guangzhou

All Listed Sponsors
lead

Janssen Research & Development, LLC

INDUSTRY

NCT05029921 - A Study of Ustekinumab (STELARA) in Chinese Participants With Moderately to Severely Active Crohn's Disease | Biotech Hunter | Biotech Hunter